Business

Beaufond PLC announces 3rd Quarter 2019-20, posts 62.16 % increase in EBITDA to USD 17.736 million of against USD 10.937 million to the corresponding period of last year.

Beaufond PLC continues to pursue its development strategy and once again delivers strong operating results, outperforming its industry. Beaufond PLC’s pharmaceutical business has recorded an excellent performance in 2020, exhibiting once again the relevance of its strategy and its operational discipline. Quarter after quarter, Beaufond PLC demonstrates its ability to
World

WHO welcomes crucial new funding for vaccines

WHO welcomes funding commitments made at the Global Vaccine Summit, hosted virtually by the UK government on 4th June. The Summit is Gavi, the Vaccine Alliance’s third pledging conference and follows the successful Berlin summit in January 2015. The new pledges will enable Gavi to protect the next generation and reduce disease inequality by reaching […]